nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—TYRO3—epilepsy syndrome	0.126	0.253	CbGaD
Vandetanib—FYN—epilepsy syndrome	0.0956	0.192	CbGaD
Vandetanib—TEK—epilepsy syndrome	0.0744	0.149	CbGaD
Vandetanib—RET—epilepsy syndrome	0.0691	0.139	CbGaD
Vandetanib—SRC—epilepsy syndrome	0.0387	0.0776	CbGaD
Vandetanib—KDR—epilepsy syndrome	0.0363	0.0729	CbGaD
Vandetanib—VEGFA—epilepsy syndrome	0.0308	0.0618	CbGaD
Vandetanib—ABCC1—Phenobarbital—epilepsy syndrome	0.0208	0.114	CbGbCtD
Vandetanib—ALB—Oxcarbazepine—epilepsy syndrome	0.0191	0.105	CbGbCtD
Vandetanib—ABCG2—epilepsy syndrome	0.019	0.0381	CbGaD
Vandetanib—ALB—Fosphenytoin—epilepsy syndrome	0.0167	0.0917	CbGbCtD
Vandetanib—ALB—Clonazepam—epilepsy syndrome	0.0151	0.083	CbGbCtD
Vandetanib—ALB—Rufinamide—epilepsy syndrome	0.0123	0.0676	CbGbCtD
Vandetanib—ALB—Phenytoin—epilepsy syndrome	0.0108	0.0591	CbGbCtD
Vandetanib—ALB—Propofol—epilepsy syndrome	0.01	0.0551	CbGbCtD
Vandetanib—ALB—Diazepam—epilepsy syndrome	0.00911	0.0499	CbGbCtD
Vandetanib—ALB—epilepsy syndrome	0.00828	0.0166	CbGaD
Vandetanib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.006	0.0329	CbGbCtD
Vandetanib—CYP3A4—Felbamate—epilepsy syndrome	0.00557	0.0306	CbGbCtD
Vandetanib—CYP3A4—Trimethadione—epilepsy syndrome	0.00557	0.0306	CbGbCtD
Vandetanib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00524	0.0288	CbGbCtD
Vandetanib—CYP3A4—Clonazepam—epilepsy syndrome	0.00474	0.026	CbGbCtD
Vandetanib—CYP3A4—Clobazam—epilepsy syndrome	0.00454	0.0249	CbGbCtD
Vandetanib—CYP3A4—Rufinamide—epilepsy syndrome	0.00386	0.0212	CbGbCtD
Vandetanib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00377	0.0207	CbGbCtD
Vandetanib—CYP3A4—Primidone—epilepsy syndrome	0.00352	0.0193	CbGbCtD
Vandetanib—CYP3A4—Phenytoin—epilepsy syndrome	0.00338	0.0185	CbGbCtD
Vandetanib—CYP3A4—Propofol—epilepsy syndrome	0.00315	0.0173	CbGbCtD
Vandetanib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00301	0.0165	CbGbCtD
Vandetanib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00301	0.0165	CbGbCtD
Vandetanib—CYP3A4—Midazolam—epilepsy syndrome	0.00297	0.0163	CbGbCtD
Vandetanib—CYP3A4—Diazepam—epilepsy syndrome	0.00285	0.0157	CbGbCtD
Vandetanib—CYP3A4—Zonisamide—epilepsy syndrome	0.00279	0.0153	CbGbCtD
Vandetanib—CYP3A4—Valproic Acid—epilepsy syndrome	0.00225	0.0123	CbGbCtD
Vandetanib—CYP3A4—Topiramate—epilepsy syndrome	0.00203	0.0111	CbGbCtD
Vandetanib—RET—autonomic nervous system—epilepsy syndrome	0.00152	0.0263	CbGeAlD
Vandetanib—ERBB3—Bortezomib—Lacosamide—epilepsy syndrome	0.000874	1	CbGdCrCtD
Vandetanib—STK35—hindbrain—epilepsy syndrome	0.000781	0.0135	CbGeAlD
Vandetanib—Bosutinib—TYRO3—epilepsy syndrome	0.00075	0.23	CrCbGaD
Vandetanib—FYN—hindbrain—epilepsy syndrome	0.000596	0.0103	CbGeAlD
Vandetanib—Bosutinib—FYN—epilepsy syndrome	0.000568	0.174	CrCbGaD
Vandetanib—TYRO3—brainstem—epilepsy syndrome	0.000537	0.00931	CbGeAlD
Vandetanib—EPHA5—forebrain—epilepsy syndrome	0.000519	0.00899	CbGeAlD
Vandetanib—TYRO3—forebrain—epilepsy syndrome	0.000519	0.00899	CbGeAlD
Vandetanib—Bosutinib—PTK2B—epilepsy syndrome	0.000483	0.148	CrCbGaD
Vandetanib—TYRO3—telencephalon—epilepsy syndrome	0.000477	0.00826	CbGeAlD
Vandetanib—EPHA5—telencephalon—epilepsy syndrome	0.000477	0.00826	CbGeAlD
Vandetanib—MAP2K5—hindbrain—epilepsy syndrome	0.000476	0.00825	CbGeAlD
Vandetanib—STK35—brainstem—epilepsy syndrome	0.000448	0.00776	CbGeAlD
Vandetanib—LTK—head—epilepsy syndrome	0.0004	0.00694	CbGeAlD
Vandetanib—FMO1—forebrain—epilepsy syndrome	0.000395	0.00685	CbGeAlD
Vandetanib—EPHA8—head—epilepsy syndrome	0.000384	0.00665	CbGeAlD
Vandetanib—ERBB3—forebrain—epilepsy syndrome	0.000381	0.00661	CbGeAlD
Vandetanib—EGFR—telencephalon—epilepsy syndrome	0.000378	0.00655	CbGeAlD
Vandetanib—EPHA5—medulla oblongata—epilepsy syndrome	0.000375	0.00649	CbGeAlD
Vandetanib—ABL1—hindbrain—epilepsy syndrome	0.000367	0.00636	CbGeAlD
Vandetanib—VEGFA—telencephalon—epilepsy syndrome	0.000365	0.00633	CbGeAlD
Vandetanib—EPHA8—nervous system—epilepsy syndrome	0.000364	0.00631	CbGeAlD
Vandetanib—ERBB3—telencephalon—epilepsy syndrome	0.000351	0.00608	CbGeAlD
Vandetanib—EPHA8—central nervous system—epilepsy syndrome	0.00035	0.00607	CbGeAlD
Vandetanib—EPHA8—cerebellum—epilepsy syndrome	0.000343	0.00594	CbGeAlD
Vandetanib—EPHA5—midbrain—epilepsy syndrome	0.000343	0.00594	CbGeAlD
Vandetanib—FYN—brainstem—epilepsy syndrome	0.000342	0.00592	CbGeAlD
Vandetanib—EPHA5—spinal cord—epilepsy syndrome	0.000334	0.00579	CbGeAlD
Vandetanib—TYRO3—spinal cord—epilepsy syndrome	0.000334	0.00579	CbGeAlD
Vandetanib—FYN—forebrain—epilepsy syndrome	0.00033	0.00571	CbGeAlD
Vandetanib—MKNK1—telencephalon—epilepsy syndrome	0.000329	0.0057	CbGeAlD
Vandetanib—AXL—telencephalon—epilepsy syndrome	0.000324	0.00561	CbGeAlD
Vandetanib—MAP4K5—forebrain—epilepsy syndrome	0.000322	0.00558	CbGeAlD
Vandetanib—EPHA6—head—epilepsy syndrome	0.00032	0.00555	CbGeAlD
Vandetanib—SLK—telencephalon—epilepsy syndrome	0.000312	0.0054	CbGeAlD
Vandetanib—EPHB6—forebrain—epilepsy syndrome	0.000308	0.00533	CbGeAlD
Vandetanib—EPHA6—nervous system—epilepsy syndrome	0.000304	0.00526	CbGeAlD
Vandetanib—FYN—telencephalon—epilepsy syndrome	0.000303	0.00525	CbGeAlD
Vandetanib—TYRO3—head—epilepsy syndrome	0.000297	0.00515	CbGeAlD
Vandetanib—EPHA5—head—epilepsy syndrome	0.000297	0.00515	CbGeAlD
Vandetanib—MAP4K5—telencephalon—epilepsy syndrome	0.000296	0.00513	CbGeAlD
Vandetanib—TEK—telencephalon—epilepsy syndrome	0.000296	0.00513	CbGeAlD
Vandetanib—LYN—head—epilepsy syndrome	0.000295	0.00512	CbGeAlD
Vandetanib—EPHA6—central nervous system—epilepsy syndrome	0.000292	0.00506	CbGeAlD
Vandetanib—BMPR1B—head—epilepsy syndrome	0.000291	0.00504	CbGeAlD
Vandetanib—MAP3K19—head—epilepsy syndrome	0.000291	0.00504	CbGeAlD
Vandetanib—LTK—brain—epilepsy syndrome	0.00029	0.00503	CbGeAlD
Vandetanib—RIPK2—medulla oblongata—epilepsy syndrome	0.000288	0.00499	CbGeAlD
Vandetanib—SRC—forebrain—epilepsy syndrome	0.000286	0.00496	CbGeAlD
Vandetanib—STK35—midbrain—epilepsy syndrome	0.000285	0.00494	CbGeAlD
Vandetanib—EPHB6—telencephalon—epilepsy syndrome	0.000283	0.00491	CbGeAlD
Vandetanib—EPHA5—nervous system—epilepsy syndrome	0.000282	0.00488	CbGeAlD
Vandetanib—TYRO3—nervous system—epilepsy syndrome	0.000282	0.00488	CbGeAlD
Vandetanib—IRAK4—medulla oblongata—epilepsy syndrome	0.000281	0.00487	CbGeAlD
Vandetanib—LYN—nervous system—epilepsy syndrome	0.00028	0.00485	CbGeAlD
Vandetanib—EPHA8—brain—epilepsy syndrome	0.000278	0.00482	CbGeAlD
Vandetanib—BMPR1B—nervous system—epilepsy syndrome	0.000276	0.00478	CbGeAlD
Vandetanib—MAP3K19—nervous system—epilepsy syndrome	0.000276	0.00478	CbGeAlD
Vandetanib—YES1—telencephalon—epilepsy syndrome	0.000274	0.00474	CbGeAlD
Vandetanib—MAP2K5—brainstem—epilepsy syndrome	0.000273	0.00473	CbGeAlD
Vandetanib—EPHA5—central nervous system—epilepsy syndrome	0.000271	0.0047	CbGeAlD
Vandetanib—TYRO3—central nervous system—epilepsy syndrome	0.000271	0.0047	CbGeAlD
Vandetanib—LYN—central nervous system—epilepsy syndrome	0.00027	0.00467	CbGeAlD
Vandetanib—BMPR1B—central nervous system—epilepsy syndrome	0.000266	0.0046	CbGeAlD
Vandetanib—MAP3K19—central nervous system—epilepsy syndrome	0.000266	0.0046	CbGeAlD
Vandetanib—TYRO3—cerebellum—epilepsy syndrome	0.000265	0.00459	CbGeAlD
Vandetanib—EPHA5—cerebellum—epilepsy syndrome	0.000265	0.00459	CbGeAlD
Vandetanib—KDR—forebrain—epilepsy syndrome	0.000263	0.00456	CbGeAlD
Vandetanib—SRC—telencephalon—epilepsy syndrome	0.000263	0.00456	CbGeAlD
Vandetanib—RIPK2—midbrain—epilepsy syndrome	0.000263	0.00456	CbGeAlD
Vandetanib—BMPR1B—cerebellum—epilepsy syndrome	0.00026	0.0045	CbGeAlD
Vandetanib—Afatinib—ABCG2—epilepsy syndrome	0.000259	0.0795	CrCbGaD
Vandetanib—MKNK1—medulla oblongata—epilepsy syndrome	0.000259	0.00448	CbGeAlD
Vandetanib—RIPK2—spinal cord—epilepsy syndrome	0.000257	0.00445	CbGeAlD
Vandetanib—VEGFA—spinal cord—epilepsy syndrome	0.000256	0.00444	CbGeAlD
Vandetanib—RET—medulla oblongata—epilepsy syndrome	0.000255	0.00443	CbGeAlD
Vandetanib—AXL—medulla oblongata—epilepsy syndrome	0.000254	0.00441	CbGeAlD
Vandetanib—ERBB3—midbrain—epilepsy syndrome	0.000252	0.00436	CbGeAlD
Vandetanib—IRAK4—spinal cord—epilepsy syndrome	0.000251	0.00434	CbGeAlD
Vandetanib—STK35—head—epilepsy syndrome	0.000247	0.00429	CbGeAlD
Vandetanib—ERBB3—spinal cord—epilepsy syndrome	0.000246	0.00426	CbGeAlD
Vandetanib—SLK—medulla oblongata—epilepsy syndrome	0.000245	0.00424	CbGeAlD
Vandetanib—MAP2K5—telencephalon—epilepsy syndrome	0.000242	0.0042	CbGeAlD
Vandetanib—FYN—medulla oblongata—epilepsy syndrome	0.000238	0.00413	CbGeAlD
Vandetanib—MKNK1—midbrain—epilepsy syndrome	0.000236	0.0041	CbGeAlD
Vandetanib—STK35—nervous system—epilepsy syndrome	0.000235	0.00406	CbGeAlD
Vandetanib—RET—midbrain—epilepsy syndrome	0.000234	0.00405	CbGeAlD
Vandetanib—TEK—medulla oblongata—epilepsy syndrome	0.000233	0.00403	CbGeAlD
Vandetanib—MAP4K5—medulla oblongata—epilepsy syndrome	0.000233	0.00403	CbGeAlD
Vandetanib—AXL—midbrain—epilepsy syndrome	0.000233	0.00403	CbGeAlD
Vandetanib—EPHA6—brain—epilepsy syndrome	0.000232	0.00402	CbGeAlD
Vandetanib—MKNK1—spinal cord—epilepsy syndrome	0.000231	0.004	CbGeAlD
Vandetanib—Bosutinib—SRC—epilepsy syndrome	0.00023	0.0705	CrCbGaD
Vandetanib—FLT4—head—epilepsy syndrome	0.000229	0.00397	CbGeAlD
Vandetanib—PLK4—brain—epilepsy syndrome	0.000229	0.00397	CbGeAlD
Vandetanib—RIPK2—head—epilepsy syndrome	0.000228	0.00395	CbGeAlD
Vandetanib—RET—spinal cord—epilepsy syndrome	0.000228	0.00395	CbGeAlD
Vandetanib—AXL—spinal cord—epilepsy syndrome	0.000227	0.00393	CbGeAlD
Vandetanib—FMO1—head—epilepsy syndrome	0.000226	0.00392	CbGeAlD
Vandetanib—STK35—central nervous system—epilepsy syndrome	0.000226	0.00391	CbGeAlD
Vandetanib—FLT3—cerebellum—epilepsy syndrome	0.000225	0.0039	CbGeAlD
Vandetanib—SLK—midbrain—epilepsy syndrome	0.000224	0.00388	CbGeAlD
Vandetanib—IRAK4—head—epilepsy syndrome	0.000223	0.00386	CbGeAlD
Vandetanib—EPHB6—medulla oblongata—epilepsy syndrome	0.000222	0.00385	CbGeAlD
Vandetanib—STK35—cerebellum—epilepsy syndrome	0.000221	0.00382	CbGeAlD
Vandetanib—SLK—spinal cord—epilepsy syndrome	0.000218	0.00379	CbGeAlD
Vandetanib—ERBB3—head—epilepsy syndrome	0.000218	0.00378	CbGeAlD
Vandetanib—FYN—midbrain—epilepsy syndrome	0.000218	0.00377	CbGeAlD
Vandetanib—EPHA5—brain—epilepsy syndrome	0.000215	0.00373	CbGeAlD
Vandetanib—TYRO3—brain—epilepsy syndrome	0.000215	0.00373	CbGeAlD
Vandetanib—ABL2—cerebellum—epilepsy syndrome	0.000215	0.00373	CbGeAlD
Vandetanib—YES1—medulla oblongata—epilepsy syndrome	0.000215	0.00372	CbGeAlD
Vandetanib—FMO1—nervous system—epilepsy syndrome	0.000215	0.00372	CbGeAlD
Vandetanib—LYN—brain—epilepsy syndrome	0.000214	0.00371	CbGeAlD
Vandetanib—MAP4K5—midbrain—epilepsy syndrome	0.000213	0.00369	CbGeAlD
Vandetanib—TEK—midbrain—epilepsy syndrome	0.000213	0.00369	CbGeAlD
Vandetanib—FYN—spinal cord—epilepsy syndrome	0.000212	0.00368	CbGeAlD
Vandetanib—IRAK4—nervous system—epilepsy syndrome	0.000211	0.00366	CbGeAlD
Vandetanib—BMPR1B—brain—epilepsy syndrome	0.000211	0.00365	CbGeAlD
Vandetanib—MAP3K19—brain—epilepsy syndrome	0.000211	0.00365	CbGeAlD
Vandetanib—ABL1—brainstem—epilepsy syndrome	0.00021	0.00365	CbGeAlD
Vandetanib—EGFR—cerebellum—epilepsy syndrome	0.00021	0.00364	CbGeAlD
Vandetanib—PDGFRB—telencephalon—epilepsy syndrome	0.00021	0.00363	CbGeAlD
Vandetanib—MAP4K5—spinal cord—epilepsy syndrome	0.000208	0.0036	CbGeAlD
Vandetanib—TEK—spinal cord—epilepsy syndrome	0.000208	0.0036	CbGeAlD
Vandetanib—ERBB3—nervous system—epilepsy syndrome	0.000207	0.00359	CbGeAlD
Vandetanib—FMO1—central nervous system—epilepsy syndrome	0.000207	0.00358	CbGeAlD
Vandetanib—MKNK1—head—epilepsy syndrome	0.000205	0.00355	CbGeAlD
Vandetanib—RIPK2—cerebellum—epilepsy syndrome	0.000204	0.00353	CbGeAlD
Vandetanib—IRAK4—central nervous system—epilepsy syndrome	0.000203	0.00352	CbGeAlD
Vandetanib—EPHB6—midbrain—epilepsy syndrome	0.000203	0.00352	CbGeAlD
Vandetanib—VEGFA—cerebellum—epilepsy syndrome	0.000203	0.00352	CbGeAlD
Vandetanib—FGR—head—epilepsy syndrome	0.000202	0.00351	CbGeAlD
Vandetanib—RET—head—epilepsy syndrome	0.000202	0.00351	CbGeAlD
Vandetanib—AXL—head—epilepsy syndrome	0.000202	0.00349	CbGeAlD
Vandetanib—ERBB3—central nervous system—epilepsy syndrome	0.000199	0.00345	CbGeAlD
Vandetanib—IRAK4—cerebellum—epilepsy syndrome	0.000199	0.00344	CbGeAlD
Vandetanib—EPHB6—spinal cord—epilepsy syndrome	0.000198	0.00344	CbGeAlD
Vandetanib—YES1—midbrain—epilepsy syndrome	0.000196	0.0034	CbGeAlD
Vandetanib—FMO3—head—epilepsy syndrome	0.000196	0.00339	CbGeAlD
Vandetanib—ERBB3—cerebellum—epilepsy syndrome	0.000195	0.00338	CbGeAlD
Vandetanib—MKNK1—nervous system—epilepsy syndrome	0.000194	0.00337	CbGeAlD
Vandetanib—RET—nervous system—epilepsy syndrome	0.000192	0.00333	CbGeAlD
Vandetanib—FGR—nervous system—epilepsy syndrome	0.000192	0.00333	CbGeAlD
Vandetanib—YES1—spinal cord—epilepsy syndrome	0.000192	0.00332	CbGeAlD
Vandetanib—AXL—nervous system—epilepsy syndrome	0.000191	0.00331	CbGeAlD
Vandetanib—MAP2K5—medulla oblongata—epilepsy syndrome	0.00019	0.0033	CbGeAlD
Vandetanib—KDR—medulla oblongata—epilepsy syndrome	0.00019	0.0033	CbGeAlD
Vandetanib—FYN—head—epilepsy syndrome	0.000189	0.00327	CbGeAlD
Vandetanib—MKNK1—central nervous system—epilepsy syndrome	0.000187	0.00324	CbGeAlD
Vandetanib—ABL1—telencephalon—epilepsy syndrome	0.000187	0.00324	CbGeAlD
Vandetanib—FMO3—nervous system—epilepsy syndrome	0.000185	0.00321	CbGeAlD
Vandetanib—RET—central nervous system—epilepsy syndrome	0.000185	0.0032	CbGeAlD
Vandetanib—FGR—central nervous system—epilepsy syndrome	0.000185	0.0032	CbGeAlD
Vandetanib—MAP4K5—head—epilepsy syndrome	0.000184	0.0032	CbGeAlD
Vandetanib—TEK—head—epilepsy syndrome	0.000184	0.0032	CbGeAlD
Vandetanib—SRC—spinal cord—epilepsy syndrome	0.000184	0.0032	CbGeAlD
Vandetanib—AXL—central nervous system—epilepsy syndrome	0.000184	0.00319	CbGeAlD
Vandetanib—Erlotinib—ABCG2—epilepsy syndrome	0.000183	0.0561	CrCbGaD
Vandetanib—MKNK1—cerebellum—epilepsy syndrome	0.000183	0.00317	CbGeAlD
Vandetanib—RET—cerebellum—epilepsy syndrome	0.000181	0.00313	CbGeAlD
Vandetanib—AXL—cerebellum—epilepsy syndrome	0.00018	0.00312	CbGeAlD
Vandetanib—STK35—brain—epilepsy syndrome	0.000179	0.00311	CbGeAlD
Vandetanib—FYN—nervous system—epilepsy syndrome	0.000179	0.0031	CbGeAlD
Vandetanib—FMO3—central nervous system—epilepsy syndrome	0.000179	0.00309	CbGeAlD
Vandetanib—EPHB6—head—epilepsy syndrome	0.000176	0.00305	CbGeAlD
Vandetanib—MAP4K5—nervous system—epilepsy syndrome	0.000175	0.00303	CbGeAlD
Vandetanib—TEK—nervous system—epilepsy syndrome	0.000175	0.00303	CbGeAlD
Vandetanib—ABL2—brain—epilepsy syndrome	0.000175	0.00303	CbGeAlD
Vandetanib—MAP2K5—midbrain—epilepsy syndrome	0.000174	0.00301	CbGeAlD
Vandetanib—KDR—midbrain—epilepsy syndrome	0.000174	0.00301	CbGeAlD
Vandetanib—SLK—cerebellum—epilepsy syndrome	0.000173	0.003	CbGeAlD
Vandetanib—FYN—central nervous system—epilepsy syndrome	0.000172	0.00299	CbGeAlD
Vandetanib—EGFR—brain—epilepsy syndrome	0.000171	0.00295	CbGeAlD
Vandetanib—YES1—head—epilepsy syndrome	0.00017	0.00295	CbGeAlD
Vandetanib—MAP2K5—spinal cord—epilepsy syndrome	0.00017	0.00294	CbGeAlD
Vandetanib—KDR—spinal cord—epilepsy syndrome	0.00017	0.00294	CbGeAlD
Vandetanib—STK10—head—epilepsy syndrome	0.000169	0.00293	CbGeAlD
Vandetanib—FYN—cerebellum—epilepsy syndrome	0.000168	0.00292	CbGeAlD
Vandetanib—MAP4K5—central nervous system—epilepsy syndrome	0.000168	0.00292	CbGeAlD
Vandetanib—TEK—central nervous system—epilepsy syndrome	0.000168	0.00292	CbGeAlD
Vandetanib—EPHB6—nervous system—epilepsy syndrome	0.000167	0.0029	CbGeAlD
Vandetanib—FLT4—brain—epilepsy syndrome	0.000166	0.00288	CbGeAlD
Vandetanib—RIPK2—brain—epilepsy syndrome	0.000165	0.00286	CbGeAlD
Vandetanib—VEGFA—brain—epilepsy syndrome	0.000165	0.00286	CbGeAlD
Vandetanib—PDGFRB—medulla oblongata—epilepsy syndrome	0.000165	0.00285	CbGeAlD
Vandetanib—MAP4K5—cerebellum—epilepsy syndrome	0.000165	0.00285	CbGeAlD
Vandetanib—TEK—cerebellum—epilepsy syndrome	0.000165	0.00285	CbGeAlD
Vandetanib—FMO1—brain—epilepsy syndrome	0.000164	0.00284	CbGeAlD
Vandetanib—SRC—head—epilepsy syndrome	0.000164	0.00284	CbGeAlD
Vandetanib—YES1—nervous system—epilepsy syndrome	0.000162	0.0028	CbGeAlD
Vandetanib—IRAK4—brain—epilepsy syndrome	0.000161	0.0028	CbGeAlD
Vandetanib—EPHB6—central nervous system—epilepsy syndrome	0.000161	0.00279	CbGeAlD
Vandetanib—STK10—nervous system—epilepsy syndrome	0.00016	0.00277	CbGeAlD
Vandetanib—ERBB3—brain—epilepsy syndrome	0.000158	0.00274	CbGeAlD
Vandetanib—EPHB6—cerebellum—epilepsy syndrome	0.000157	0.00273	CbGeAlD
Vandetanib—YES1—central nervous system—epilepsy syndrome	0.000155	0.00269	CbGeAlD
Vandetanib—SRC—nervous system—epilepsy syndrome	0.000155	0.00269	CbGeAlD
Vandetanib—STK10—central nervous system—epilepsy syndrome	0.000154	0.00267	CbGeAlD
Vandetanib—YES1—cerebellum—epilepsy syndrome	0.000152	0.00263	CbGeAlD
Vandetanib—MAP2K5—head—epilepsy syndrome	0.000151	0.00261	CbGeAlD
Vandetanib—KDR—head—epilepsy syndrome	0.000151	0.00261	CbGeAlD
Vandetanib—STK10—cerebellum—epilepsy syndrome	0.000151	0.00261	CbGeAlD
Vandetanib—PDGFRB—midbrain—epilepsy syndrome	0.00015	0.00261	CbGeAlD
Vandetanib—SRC—central nervous system—epilepsy syndrome	0.00015	0.00259	CbGeAlD
Vandetanib—MKNK1—brain—epilepsy syndrome	0.000149	0.00257	CbGeAlD
Vandetanib—PDGFRB—spinal cord—epilepsy syndrome	0.000147	0.00254	CbGeAlD
Vandetanib—ABL1—medulla oblongata—epilepsy syndrome	0.000147	0.00254	CbGeAlD
Vandetanib—FGR—brain—epilepsy syndrome	0.000147	0.00254	CbGeAlD
Vandetanib—RET—brain—epilepsy syndrome	0.000147	0.00254	CbGeAlD
Vandetanib—SRC—cerebellum—epilepsy syndrome	0.000146	0.00253	CbGeAlD
Vandetanib—AXL—brain—epilepsy syndrome	0.000146	0.00253	CbGeAlD
Vandetanib—KDR—nervous system—epilepsy syndrome	0.000143	0.00248	CbGeAlD
Vandetanib—MAP2K5—nervous system—epilepsy syndrome	0.000143	0.00248	CbGeAlD
Vandetanib—ABCC1—telencephalon—epilepsy syndrome	0.000142	0.00247	CbGeAlD
Vandetanib—FMO3—brain—epilepsy syndrome	0.000142	0.00246	CbGeAlD
Vandetanib—SLK—brain—epilepsy syndrome	0.000141	0.00244	CbGeAlD
Vandetanib—ORM1—spinal cord—epilepsy syndrome	0.000138	0.00239	CbGeAlD
Vandetanib—KDR—central nervous system—epilepsy syndrome	0.000138	0.00238	CbGeAlD
Vandetanib—MAP2K5—central nervous system—epilepsy syndrome	0.000138	0.00238	CbGeAlD
Vandetanib—FYN—brain—epilepsy syndrome	0.000137	0.00237	CbGeAlD
Vandetanib—KDR—cerebellum—epilepsy syndrome	0.000134	0.00233	CbGeAlD
Vandetanib—MAP2K5—cerebellum—epilepsy syndrome	0.000134	0.00233	CbGeAlD
Vandetanib—ABL1—midbrain—epilepsy syndrome	0.000134	0.00232	CbGeAlD
Vandetanib—MAP4K5—brain—epilepsy syndrome	0.000134	0.00232	CbGeAlD
Vandetanib—TEK—brain—epilepsy syndrome	0.000134	0.00232	CbGeAlD
Vandetanib—ABL1—spinal cord—epilepsy syndrome	0.000131	0.00227	CbGeAlD
Vandetanib—PDGFRB—head—epilepsy syndrome	0.00013	0.00226	CbGeAlD
Vandetanib—EPHB6—brain—epilepsy syndrome	0.000128	0.00221	CbGeAlD
Vandetanib—PDGFRB—nervous system—epilepsy syndrome	0.000124	0.00214	CbGeAlD
Vandetanib—YES1—brain—epilepsy syndrome	0.000123	0.00214	CbGeAlD
Vandetanib—STK10—brain—epilepsy syndrome	0.000122	0.00212	CbGeAlD
Vandetanib—PDGFRB—central nervous system—epilepsy syndrome	0.000119	0.00206	CbGeAlD
Vandetanib—SRC—brain—epilepsy syndrome	0.000119	0.00206	CbGeAlD
Vandetanib—ABCG2—telencephalon—epilepsy syndrome	0.000118	0.00204	CbGeAlD
Vandetanib—PDGFRB—cerebellum—epilepsy syndrome	0.000116	0.00202	CbGeAlD
Vandetanib—ABL1—head—epilepsy syndrome	0.000116	0.00202	CbGeAlD
Vandetanib—ORM1—nervous system—epilepsy syndrome	0.000116	0.00201	CbGeAlD
Vandetanib—Gefitinib—ABCG2—epilepsy syndrome	0.000115	0.0351	CrCbGaD
Vandetanib—ORM1—central nervous system—epilepsy syndrome	0.000112	0.00194	CbGeAlD
Vandetanib—ABL1—nervous system—epilepsy syndrome	0.00011	0.00191	CbGeAlD
Vandetanib—MAP2K5—brain—epilepsy syndrome	0.000109	0.00189	CbGeAlD
Vandetanib—KDR—brain—epilepsy syndrome	0.000109	0.00189	CbGeAlD
Vandetanib—Afatinib—ABCB1—epilepsy syndrome	0.000108	0.0331	CrCbGaD
Vandetanib—Erlotinib—CYP2D6—epilepsy syndrome	0.000107	0.0327	CrCbGaD
Vandetanib—ABL1—central nervous system—epilepsy syndrome	0.000106	0.00184	CbGeAlD
Vandetanib—ABL1—cerebellum—epilepsy syndrome	0.000104	0.0018	CbGeAlD
Vandetanib—PDGFRB—brain—epilepsy syndrome	9.46e-05	0.00164	CbGeAlD
Vandetanib—ABCG2—medulla oblongata—epilepsy syndrome	9.25e-05	0.0016	CbGeAlD
Vandetanib—Gefitinib—CYP2C19—epilepsy syndrome	9e-05	0.0276	CrCbGaD
Vandetanib—ABCG2—midbrain—epilepsy syndrome	8.46e-05	0.00147	CbGeAlD
Vandetanib—ABL1—brain—epilepsy syndrome	8.43e-05	0.00146	CbGeAlD
Vandetanib—ABCG2—spinal cord—epilepsy syndrome	8.25e-05	0.00143	CbGeAlD
Vandetanib—Erlotinib—ALB—epilepsy syndrome	7.98e-05	0.0245	CrCbGaD
Vandetanib—ABCC1—cerebellum—epilepsy syndrome	7.9e-05	0.00137	CbGeAlD
Vandetanib—ALB—brain—epilepsy syndrome	7.78e-05	0.00135	CbGeAlD
Vandetanib—Erlotinib—ABCB1—epilepsy syndrome	7.61e-05	0.0234	CrCbGaD
Vandetanib—Gefitinib—CYP2D6—epilepsy syndrome	6.67e-05	0.0205	CrCbGaD
Vandetanib—ABCG2—cerebellum—epilepsy syndrome	6.54e-05	0.00113	CbGeAlD
Vandetanib—ABCC1—brain—epilepsy syndrome	6.42e-05	0.00111	CbGeAlD
Vandetanib—ABCG2—brain—epilepsy syndrome	5.31e-05	0.000921	CbGeAlD
Vandetanib—Gefitinib—ALB—epilepsy syndrome	4.99e-05	0.0153	CrCbGaD
Vandetanib—CYP3A4—nervous system—epilepsy syndrome	4.84e-05	0.000839	CbGeAlD
Vandetanib—Gefitinib—ABCB1—epilepsy syndrome	4.77e-05	0.0146	CrCbGaD
Vandetanib—Bosutinib—ABCB1—epilepsy syndrome	4.69e-05	0.0144	CrCbGaD
Vandetanib—CYP3A4—central nervous system—epilepsy syndrome	4.66e-05	0.000808	CbGeAlD
Vandetanib—Abdominal pain—Carbamazepine—epilepsy syndrome	3.73e-05	0.000274	CcSEcCtD
Vandetanib—Body temperature increased—Carbamazepine—epilepsy syndrome	3.73e-05	0.000274	CcSEcCtD
Vandetanib—Diarrhoea—Diazepam—epilepsy syndrome	3.73e-05	0.000274	CcSEcCtD
Vandetanib—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	3.73e-05	0.000274	CcSEcCtD
Vandetanib—Sinusitis—Topiramate—epilepsy syndrome	3.72e-05	0.000273	CcSEcCtD
Vandetanib—Rash—Levetiracetam—epilepsy syndrome	3.71e-05	0.000272	CcSEcCtD
Vandetanib—Dermatitis—Levetiracetam—epilepsy syndrome	3.71e-05	0.000272	CcSEcCtD
Vandetanib—Asthenia—Zonisamide—epilepsy syndrome	3.7e-05	0.000272	CcSEcCtD
Vandetanib—Mental disorder—Gabapentin—epilepsy syndrome	3.7e-05	0.000272	CcSEcCtD
Vandetanib—Dry mouth—Valproic Acid—epilepsy syndrome	3.69e-05	0.000271	CcSEcCtD
Vandetanib—Headache—Levetiracetam—epilepsy syndrome	3.68e-05	0.000271	CcSEcCtD
Vandetanib—Malnutrition—Gabapentin—epilepsy syndrome	3.68e-05	0.00027	CcSEcCtD
Vandetanib—Dizziness—Vigabatrin—epilepsy syndrome	3.66e-05	0.000269	CcSEcCtD
Vandetanib—Pruritus—Zonisamide—epilepsy syndrome	3.65e-05	0.000268	CcSEcCtD
Vandetanib—Oedema—Valproic Acid—epilepsy syndrome	3.62e-05	0.000266	CcSEcCtD
Vandetanib—Bradycardia—Topiramate—epilepsy syndrome	3.62e-05	0.000266	CcSEcCtD
Vandetanib—Nausea—Propofol—epilepsy syndrome	3.62e-05	0.000266	CcSEcCtD
Vandetanib—Vomiting—Fosphenytoin—epilepsy syndrome	3.61e-05	0.000265	CcSEcCtD
Vandetanib—Diarrhoea—Felbamate—epilepsy syndrome	3.61e-05	0.000265	CcSEcCtD
Vandetanib—Abdominal pain—Lamotrigine—epilepsy syndrome	3.6e-05	0.000265	CcSEcCtD
Vandetanib—Body temperature increased—Lamotrigine—epilepsy syndrome	3.6e-05	0.000265	CcSEcCtD
Vandetanib—Dysgeusia—Gabapentin—epilepsy syndrome	3.6e-05	0.000265	CcSEcCtD
Vandetanib—Dizziness—Diazepam—epilepsy syndrome	3.6e-05	0.000265	CcSEcCtD
Vandetanib—Infection—Valproic Acid—epilepsy syndrome	3.6e-05	0.000264	CcSEcCtD
Vandetanib—Rash—Fosphenytoin—epilepsy syndrome	3.58e-05	0.000263	CcSEcCtD
Vandetanib—Dermatitis—Fosphenytoin—epilepsy syndrome	3.58e-05	0.000263	CcSEcCtD
Vandetanib—Haemoglobin—Topiramate—epilepsy syndrome	3.57e-05	0.000262	CcSEcCtD
Vandetanib—Asthenia—Clonazepam—epilepsy syndrome	3.57e-05	0.000262	CcSEcCtD
Vandetanib—Headache—Fosphenytoin—epilepsy syndrome	3.56e-05	0.000261	CcSEcCtD
Vandetanib—Haemorrhage—Topiramate—epilepsy syndrome	3.56e-05	0.000261	CcSEcCtD
Vandetanib—Nervous system disorder—Valproic Acid—epilepsy syndrome	3.55e-05	0.000261	CcSEcCtD
Vandetanib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	3.55e-05	0.00026	CcSEcCtD
Vandetanib—Asthenia—Phenytoin—epilepsy syndrome	3.54e-05	0.00026	CcSEcCtD
Vandetanib—Nausea—Midazolam—epilepsy syndrome	3.54e-05	0.00026	CcSEcCtD
Vandetanib—Muscle spasms—Gabapentin—epilepsy syndrome	3.54e-05	0.00026	CcSEcCtD
Vandetanib—Diarrhoea—Zonisamide—epilepsy syndrome	3.53e-05	0.000259	CcSEcCtD
Vandetanib—Loss of consciousness—Pregabalin—epilepsy syndrome	3.53e-05	0.000259	CcSEcCtD
Vandetanib—Asthenia—Oxcarbazepine—epilepsy syndrome	3.53e-05	0.000259	CcSEcCtD
Vandetanib—Pruritus—Clonazepam—epilepsy syndrome	3.52e-05	0.000258	CcSEcCtD
Vandetanib—Vomiting—Vigabatrin—epilepsy syndrome	3.52e-05	0.000258	CcSEcCtD
Vandetanib—Skin disorder—Valproic Acid—epilepsy syndrome	3.52e-05	0.000258	CcSEcCtD
Vandetanib—Urinary tract disorder—Topiramate—epilepsy syndrome	3.51e-05	0.000258	CcSEcCtD
Vandetanib—Cough—Pregabalin—epilepsy syndrome	3.5e-05	0.000257	CcSEcCtD
Vandetanib—Pruritus—Phenytoin—epilepsy syndrome	3.5e-05	0.000257	CcSEcCtD
Vandetanib—Nausea—Levetiracetam—epilepsy syndrome	3.49e-05	0.000257	CcSEcCtD
Vandetanib—Rash—Vigabatrin—epilepsy syndrome	3.49e-05	0.000256	CcSEcCtD
Vandetanib—Dizziness—Felbamate—epilepsy syndrome	3.49e-05	0.000256	CcSEcCtD
Vandetanib—Dermatitis—Vigabatrin—epilepsy syndrome	3.49e-05	0.000256	CcSEcCtD
Vandetanib—Urethral disorder—Topiramate—epilepsy syndrome	3.49e-05	0.000256	CcSEcCtD
Vandetanib—Pruritus—Oxcarbazepine—epilepsy syndrome	3.48e-05	0.000255	CcSEcCtD
Vandetanib—Convulsion—Pregabalin—epilepsy syndrome	3.48e-05	0.000255	CcSEcCtD
Vandetanib—Vision blurred—Gabapentin—epilepsy syndrome	3.47e-05	0.000255	CcSEcCtD
Vandetanib—Headache—Vigabatrin—epilepsy syndrome	3.47e-05	0.000255	CcSEcCtD
Vandetanib—Hypertension—Pregabalin—epilepsy syndrome	3.46e-05	0.000254	CcSEcCtD
Vandetanib—Vomiting—Diazepam—epilepsy syndrome	3.46e-05	0.000254	CcSEcCtD
Vandetanib—Tremor—Gabapentin—epilepsy syndrome	3.45e-05	0.000253	CcSEcCtD
Vandetanib—Rash—Diazepam—epilepsy syndrome	3.43e-05	0.000252	CcSEcCtD
Vandetanib—Dermatitis—Diazepam—epilepsy syndrome	3.43e-05	0.000252	CcSEcCtD
Vandetanib—Visual impairment—Topiramate—epilepsy syndrome	3.43e-05	0.000252	CcSEcCtD
Vandetanib—Arthralgia—Pregabalin—epilepsy syndrome	3.42e-05	0.000251	CcSEcCtD
Vandetanib—Chest pain—Pregabalin—epilepsy syndrome	3.42e-05	0.000251	CcSEcCtD
Vandetanib—Dizziness—Zonisamide—epilepsy syndrome	3.41e-05	0.000251	CcSEcCtD
Vandetanib—Headache—Diazepam—epilepsy syndrome	3.41e-05	0.000251	CcSEcCtD
Vandetanib—Anxiety—Pregabalin—epilepsy syndrome	3.4e-05	0.00025	CcSEcCtD
Vandetanib—Diarrhoea—Clonazepam—epilepsy syndrome	3.4e-05	0.00025	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	3.39e-05	0.000249	CcSEcCtD
Vandetanib—Asthenia—Carbamazepine—epilepsy syndrome	3.38e-05	0.000248	CcSEcCtD
Vandetanib—Diarrhoea—Phenytoin—epilepsy syndrome	3.38e-05	0.000248	CcSEcCtD
Vandetanib—Nausea—Fosphenytoin—epilepsy syndrome	3.37e-05	0.000248	CcSEcCtD
Vandetanib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.36e-05	0.000247	CcSEcCtD
Vandetanib—Erythema multiforme—Topiramate—epilepsy syndrome	3.36e-05	0.000247	CcSEcCtD
Vandetanib—Vomiting—Felbamate—epilepsy syndrome	3.35e-05	0.000246	CcSEcCtD
Vandetanib—Dry mouth—Pregabalin—epilepsy syndrome	3.34e-05	0.000245	CcSEcCtD
Vandetanib—Pruritus—Carbamazepine—epilepsy syndrome	3.34e-05	0.000245	CcSEcCtD
Vandetanib—Rash—Felbamate—epilepsy syndrome	3.32e-05	0.000244	CcSEcCtD
Vandetanib—Eye disorder—Topiramate—epilepsy syndrome	3.32e-05	0.000244	CcSEcCtD
Vandetanib—Dermatitis—Felbamate—epilepsy syndrome	3.32e-05	0.000244	CcSEcCtD
Vandetanib—Headache—Felbamate—epilepsy syndrome	3.3e-05	0.000243	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	3.3e-05	0.000242	CcSEcCtD
Vandetanib—Cardiac disorder—Topiramate—epilepsy syndrome	3.3e-05	0.000242	CcSEcCtD
Vandetanib—Dizziness—Clonazepam—epilepsy syndrome	3.29e-05	0.000242	CcSEcCtD
Vandetanib—Nausea—Vigabatrin—epilepsy syndrome	3.29e-05	0.000241	CcSEcCtD
Vandetanib—Vomiting—Zonisamide—epilepsy syndrome	3.28e-05	0.000241	CcSEcCtD
Vandetanib—Insomnia—Valproic Acid—epilepsy syndrome	3.28e-05	0.000241	CcSEcCtD
Vandetanib—Oedema—Pregabalin—epilepsy syndrome	3.27e-05	0.00024	CcSEcCtD
Vandetanib—Asthenia—Lamotrigine—epilepsy syndrome	3.27e-05	0.00024	CcSEcCtD
Vandetanib—Dizziness—Phenytoin—epilepsy syndrome	3.27e-05	0.00024	CcSEcCtD
Vandetanib—Rash—Zonisamide—epilepsy syndrome	3.25e-05	0.000239	CcSEcCtD
Vandetanib—Infection—Pregabalin—epilepsy syndrome	3.25e-05	0.000239	CcSEcCtD
Vandetanib—Paraesthesia—Valproic Acid—epilepsy syndrome	3.25e-05	0.000239	CcSEcCtD
Vandetanib—Dermatitis—Zonisamide—epilepsy syndrome	3.25e-05	0.000239	CcSEcCtD
Vandetanib—Dizziness—Oxcarbazepine—epilepsy syndrome	3.25e-05	0.000239	CcSEcCtD
Vandetanib—Nausea—Diazepam—epilepsy syndrome	3.24e-05	0.000238	CcSEcCtD
Vandetanib—Loss of consciousness—Gabapentin—epilepsy syndrome	3.23e-05	0.000237	CcSEcCtD
Vandetanib—Headache—Zonisamide—epilepsy syndrome	3.23e-05	0.000237	CcSEcCtD
Vandetanib—Dyspnoea—Valproic Acid—epilepsy syndrome	3.23e-05	0.000237	CcSEcCtD
Vandetanib—Diarrhoea—Carbamazepine—epilepsy syndrome	3.23e-05	0.000237	CcSEcCtD
Vandetanib—Angiopathy—Topiramate—epilepsy syndrome	3.23e-05	0.000237	CcSEcCtD
Vandetanib—Pruritus—Lamotrigine—epilepsy syndrome	3.22e-05	0.000237	CcSEcCtD
Vandetanib—Nervous system disorder—Pregabalin—epilepsy syndrome	3.21e-05	0.000236	CcSEcCtD
Vandetanib—Cough—Gabapentin—epilepsy syndrome	3.21e-05	0.000236	CcSEcCtD
Vandetanib—Thrombocytopenia—Pregabalin—epilepsy syndrome	3.21e-05	0.000235	CcSEcCtD
Vandetanib—Mediastinal disorder—Topiramate—epilepsy syndrome	3.2e-05	0.000235	CcSEcCtD
Vandetanib—Dyspepsia—Valproic Acid—epilepsy syndrome	3.19e-05	0.000234	CcSEcCtD
Vandetanib—Convulsion—Gabapentin—epilepsy syndrome	3.19e-05	0.000234	CcSEcCtD
Vandetanib—Skin disorder—Pregabalin—epilepsy syndrome	3.18e-05	0.000234	CcSEcCtD
Vandetanib—Hypertension—Gabapentin—epilepsy syndrome	3.18e-05	0.000233	CcSEcCtD
Vandetanib—Vomiting—Clonazepam—epilepsy syndrome	3.16e-05	0.000232	CcSEcCtD
Vandetanib—Decreased appetite—Valproic Acid—epilepsy syndrome	3.15e-05	0.000231	CcSEcCtD
Vandetanib—Alopecia—Topiramate—epilepsy syndrome	3.14e-05	0.000231	CcSEcCtD
Vandetanib—Vomiting—Phenytoin—epilepsy syndrome	3.14e-05	0.000231	CcSEcCtD
Vandetanib—Rash—Clonazepam—epilepsy syndrome	3.14e-05	0.00023	CcSEcCtD
Vandetanib—Dermatitis—Clonazepam—epilepsy syndrome	3.13e-05	0.00023	CcSEcCtD
Vandetanib—Arthralgia—Gabapentin—epilepsy syndrome	3.13e-05	0.00023	CcSEcCtD
Vandetanib—Chest pain—Gabapentin—epilepsy syndrome	3.13e-05	0.00023	CcSEcCtD
Vandetanib—Nausea—Felbamate—epilepsy syndrome	3.13e-05	0.00023	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.13e-05	0.00023	CcSEcCtD
Vandetanib—Vomiting—Oxcarbazepine—epilepsy syndrome	3.12e-05	0.000229	CcSEcCtD
Vandetanib—Fatigue—Valproic Acid—epilepsy syndrome	3.12e-05	0.000229	CcSEcCtD
Vandetanib—Anxiety—Gabapentin—epilepsy syndrome	3.12e-05	0.000229	CcSEcCtD
Vandetanib—Dizziness—Carbamazepine—epilepsy syndrome	3.12e-05	0.000229	CcSEcCtD
Vandetanib—Diarrhoea—Lamotrigine—epilepsy syndrome	3.12e-05	0.000229	CcSEcCtD
Vandetanib—Headache—Clonazepam—epilepsy syndrome	3.12e-05	0.000229	CcSEcCtD
Vandetanib—Rash—Phenytoin—epilepsy syndrome	3.12e-05	0.000229	CcSEcCtD
Vandetanib—Mental disorder—Topiramate—epilepsy syndrome	3.11e-05	0.000229	CcSEcCtD
Vandetanib—Dermatitis—Phenytoin—epilepsy syndrome	3.11e-05	0.000229	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.11e-05	0.000228	CcSEcCtD
Vandetanib—Rash—Oxcarbazepine—epilepsy syndrome	3.1e-05	0.000228	CcSEcCtD
Vandetanib—Pain—Valproic Acid—epilepsy syndrome	3.1e-05	0.000227	CcSEcCtD
Vandetanib—Constipation—Valproic Acid—epilepsy syndrome	3.1e-05	0.000227	CcSEcCtD
Vandetanib—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.1e-05	0.000227	CcSEcCtD
Vandetanib—Headache—Phenytoin—epilepsy syndrome	3.1e-05	0.000227	CcSEcCtD
Vandetanib—Malnutrition—Topiramate—epilepsy syndrome	3.1e-05	0.000227	CcSEcCtD
Vandetanib—Headache—Oxcarbazepine—epilepsy syndrome	3.08e-05	0.000226	CcSEcCtD
Vandetanib—Nausea—Zonisamide—epilepsy syndrome	3.07e-05	0.000225	CcSEcCtD
Vandetanib—Dry mouth—Gabapentin—epilepsy syndrome	3.06e-05	0.000225	CcSEcCtD
Vandetanib—Dysgeusia—Topiramate—epilepsy syndrome	3.03e-05	0.000223	CcSEcCtD
Vandetanib—Dizziness—Lamotrigine—epilepsy syndrome	3.01e-05	0.000221	CcSEcCtD
Vandetanib—Oedema—Gabapentin—epilepsy syndrome	3e-05	0.00022	CcSEcCtD
Vandetanib—Vomiting—Carbamazepine—epilepsy syndrome	3e-05	0.00022	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	2.98e-05	0.000219	CcSEcCtD
Vandetanib—Infection—Gabapentin—epilepsy syndrome	2.98e-05	0.000219	CcSEcCtD
Vandetanib—Muscle spasms—Topiramate—epilepsy syndrome	2.98e-05	0.000218	CcSEcCtD
Vandetanib—Rash—Carbamazepine—epilepsy syndrome	2.97e-05	0.000218	CcSEcCtD
Vandetanib—Dermatitis—Carbamazepine—epilepsy syndrome	2.97e-05	0.000218	CcSEcCtD
Vandetanib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	2.96e-05	0.000217	CcSEcCtD
Vandetanib—Insomnia—Pregabalin—epilepsy syndrome	2.96e-05	0.000217	CcSEcCtD
Vandetanib—Nausea—Clonazepam—epilepsy syndrome	2.95e-05	0.000217	CcSEcCtD
Vandetanib—Headache—Carbamazepine—epilepsy syndrome	2.95e-05	0.000217	CcSEcCtD
Vandetanib—Nervous system disorder—Gabapentin—epilepsy syndrome	2.94e-05	0.000216	CcSEcCtD
Vandetanib—Paraesthesia—Pregabalin—epilepsy syndrome	2.94e-05	0.000216	CcSEcCtD
Vandetanib—Thrombocytopenia—Gabapentin—epilepsy syndrome	2.94e-05	0.000216	CcSEcCtD
Vandetanib—Nausea—Phenytoin—epilepsy syndrome	2.93e-05	0.000215	CcSEcCtD
Vandetanib—Dyspnoea—Pregabalin—epilepsy syndrome	2.92e-05	0.000214	CcSEcCtD
Vandetanib—Nausea—Oxcarbazepine—epilepsy syndrome	2.92e-05	0.000214	CcSEcCtD
Vandetanib—Vision blurred—Topiramate—epilepsy syndrome	2.92e-05	0.000214	CcSEcCtD
Vandetanib—Skin disorder—Gabapentin—epilepsy syndrome	2.92e-05	0.000214	CcSEcCtD
Vandetanib—Tremor—Topiramate—epilepsy syndrome	2.9e-05	0.000213	CcSEcCtD
Vandetanib—Vomiting—Lamotrigine—epilepsy syndrome	2.9e-05	0.000213	CcSEcCtD
Vandetanib—Rash—Lamotrigine—epilepsy syndrome	2.87e-05	0.000211	CcSEcCtD
Vandetanib—Dermatitis—Lamotrigine—epilepsy syndrome	2.87e-05	0.000211	CcSEcCtD
Vandetanib—Abdominal pain—Valproic Acid—epilepsy syndrome	2.86e-05	0.00021	CcSEcCtD
Vandetanib—Body temperature increased—Valproic Acid—epilepsy syndrome	2.86e-05	0.00021	CcSEcCtD
Vandetanib—Headache—Lamotrigine—epilepsy syndrome	2.86e-05	0.00021	CcSEcCtD
Vandetanib—Decreased appetite—Pregabalin—epilepsy syndrome	2.85e-05	0.000209	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	2.83e-05	0.000208	CcSEcCtD
Vandetanib—Fatigue—Pregabalin—epilepsy syndrome	2.82e-05	0.000207	CcSEcCtD
Vandetanib—Nausea—Carbamazepine—epilepsy syndrome	2.8e-05	0.000206	CcSEcCtD
Vandetanib—Pain—Pregabalin—epilepsy syndrome	2.8e-05	0.000206	CcSEcCtD
Vandetanib—Constipation—Pregabalin—epilepsy syndrome	2.8e-05	0.000206	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	2.74e-05	0.000201	CcSEcCtD
Vandetanib—Loss of consciousness—Topiramate—epilepsy syndrome	2.72e-05	0.0002	CcSEcCtD
Vandetanib—Insomnia—Gabapentin—epilepsy syndrome	2.72e-05	0.000199	CcSEcCtD
Vandetanib—Nausea—Lamotrigine—epilepsy syndrome	2.71e-05	0.000199	CcSEcCtD
Vandetanib—Cough—Topiramate—epilepsy syndrome	2.7e-05	0.000198	CcSEcCtD
Vandetanib—Paraesthesia—Gabapentin—epilepsy syndrome	2.7e-05	0.000198	CcSEcCtD
Vandetanib—Convulsion—Topiramate—epilepsy syndrome	2.68e-05	0.000197	CcSEcCtD
Vandetanib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	2.68e-05	0.000197	CcSEcCtD
Vandetanib—Dyspnoea—Gabapentin—epilepsy syndrome	2.68e-05	0.000197	CcSEcCtD
Vandetanib—Hypertension—Topiramate—epilepsy syndrome	2.67e-05	0.000196	CcSEcCtD
Vandetanib—Dyspepsia—Gabapentin—epilepsy syndrome	2.64e-05	0.000194	CcSEcCtD
Vandetanib—Arthralgia—Topiramate—epilepsy syndrome	2.63e-05	0.000193	CcSEcCtD
Vandetanib—Chest pain—Topiramate—epilepsy syndrome	2.63e-05	0.000193	CcSEcCtD
Vandetanib—Anxiety—Topiramate—epilepsy syndrome	2.63e-05	0.000193	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	2.62e-05	0.000192	CcSEcCtD
Vandetanib—Decreased appetite—Gabapentin—epilepsy syndrome	2.61e-05	0.000192	CcSEcCtD
Vandetanib—Asthenia—Valproic Acid—epilepsy syndrome	2.6e-05	0.000191	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.59e-05	0.00019	CcSEcCtD
Vandetanib—Fatigue—Gabapentin—epilepsy syndrome	2.59e-05	0.00019	CcSEcCtD
Vandetanib—Body temperature increased—Pregabalin—epilepsy syndrome	2.59e-05	0.00019	CcSEcCtD
Vandetanib—Abdominal pain—Pregabalin—epilepsy syndrome	2.59e-05	0.00019	CcSEcCtD
Vandetanib—Dry mouth—Topiramate—epilepsy syndrome	2.58e-05	0.000189	CcSEcCtD
Vandetanib—Pain—Gabapentin—epilepsy syndrome	2.57e-05	0.000189	CcSEcCtD
Vandetanib—Constipation—Gabapentin—epilepsy syndrome	2.57e-05	0.000189	CcSEcCtD
Vandetanib—Pruritus—Valproic Acid—epilepsy syndrome	2.56e-05	0.000188	CcSEcCtD
Vandetanib—Oedema—Topiramate—epilepsy syndrome	2.53e-05	0.000185	CcSEcCtD
Vandetanib—Infection—Topiramate—epilepsy syndrome	2.51e-05	0.000184	CcSEcCtD
Vandetanib—Diarrhoea—Valproic Acid—epilepsy syndrome	2.48e-05	0.000182	CcSEcCtD
Vandetanib—Nervous system disorder—Topiramate—epilepsy syndrome	2.48e-05	0.000182	CcSEcCtD
Vandetanib—Thrombocytopenia—Topiramate—epilepsy syndrome	2.47e-05	0.000182	CcSEcCtD
Vandetanib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.46e-05	0.00018	CcSEcCtD
Vandetanib—Skin disorder—Topiramate—epilepsy syndrome	2.45e-05	0.00018	CcSEcCtD
Vandetanib—Dizziness—Valproic Acid—epilepsy syndrome	2.39e-05	0.000176	CcSEcCtD
Vandetanib—Abdominal pain—Gabapentin—epilepsy syndrome	2.37e-05	0.000174	CcSEcCtD
Vandetanib—Body temperature increased—Gabapentin—epilepsy syndrome	2.37e-05	0.000174	CcSEcCtD
Vandetanib—Asthenia—Pregabalin—epilepsy syndrome	2.35e-05	0.000172	CcSEcCtD
Vandetanib—Pruritus—Pregabalin—epilepsy syndrome	2.32e-05	0.00017	CcSEcCtD
Vandetanib—Vomiting—Valproic Acid—epilepsy syndrome	2.3e-05	0.000169	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.3e-05	0.000169	CcSEcCtD
Vandetanib—Insomnia—Topiramate—epilepsy syndrome	2.28e-05	0.000168	CcSEcCtD
Vandetanib—Rash—Valproic Acid—epilepsy syndrome	2.28e-05	0.000168	CcSEcCtD
Vandetanib—Dermatitis—Valproic Acid—epilepsy syndrome	2.28e-05	0.000168	CcSEcCtD
Vandetanib—Headache—Valproic Acid—epilepsy syndrome	2.27e-05	0.000167	CcSEcCtD
Vandetanib—Paraesthesia—Topiramate—epilepsy syndrome	2.27e-05	0.000167	CcSEcCtD
Vandetanib—Dyspnoea—Topiramate—epilepsy syndrome	2.25e-05	0.000165	CcSEcCtD
Vandetanib—Diarrhoea—Pregabalin—epilepsy syndrome	2.24e-05	0.000164	CcSEcCtD
Vandetanib—Dyspepsia—Topiramate—epilepsy syndrome	2.22e-05	0.000163	CcSEcCtD
Vandetanib—Decreased appetite—Topiramate—epilepsy syndrome	2.2e-05	0.000161	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.18e-05	0.00016	CcSEcCtD
Vandetanib—Fatigue—Topiramate—epilepsy syndrome	2.18e-05	0.00016	CcSEcCtD
Vandetanib—Dizziness—Pregabalin—epilepsy syndrome	2.17e-05	0.000159	CcSEcCtD
Vandetanib—Pain—Topiramate—epilepsy syndrome	2.16e-05	0.000159	CcSEcCtD
Vandetanib—Constipation—Topiramate—epilepsy syndrome	2.16e-05	0.000159	CcSEcCtD
Vandetanib—Asthenia—Gabapentin—epilepsy syndrome	2.15e-05	0.000158	CcSEcCtD
Vandetanib—Nausea—Valproic Acid—epilepsy syndrome	2.15e-05	0.000158	CcSEcCtD
Vandetanib—Pruritus—Gabapentin—epilepsy syndrome	2.12e-05	0.000156	CcSEcCtD
Vandetanib—Vomiting—Pregabalin—epilepsy syndrome	2.08e-05	0.000153	CcSEcCtD
Vandetanib—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.07e-05	0.000152	CcSEcCtD
Vandetanib—Rash—Pregabalin—epilepsy syndrome	2.06e-05	0.000152	CcSEcCtD
Vandetanib—Dermatitis—Pregabalin—epilepsy syndrome	2.06e-05	0.000151	CcSEcCtD
Vandetanib—Diarrhoea—Gabapentin—epilepsy syndrome	2.05e-05	0.000151	CcSEcCtD
Vandetanib—Headache—Pregabalin—epilepsy syndrome	2.05e-05	0.000151	CcSEcCtD
Vandetanib—Body temperature increased—Topiramate—epilepsy syndrome	2e-05	0.000147	CcSEcCtD
Vandetanib—Abdominal pain—Topiramate—epilepsy syndrome	2e-05	0.000147	CcSEcCtD
Vandetanib—Dizziness—Gabapentin—epilepsy syndrome	1.99e-05	0.000146	CcSEcCtD
Vandetanib—Nausea—Pregabalin—epilepsy syndrome	1.94e-05	0.000143	CcSEcCtD
Vandetanib—Vomiting—Gabapentin—epilepsy syndrome	1.91e-05	0.00014	CcSEcCtD
Vandetanib—Rash—Gabapentin—epilepsy syndrome	1.89e-05	0.000139	CcSEcCtD
Vandetanib—Dermatitis—Gabapentin—epilepsy syndrome	1.89e-05	0.000139	CcSEcCtD
Vandetanib—Headache—Gabapentin—epilepsy syndrome	1.88e-05	0.000138	CcSEcCtD
Vandetanib—Asthenia—Topiramate—epilepsy syndrome	1.81e-05	0.000133	CcSEcCtD
Vandetanib—Pruritus—Topiramate—epilepsy syndrome	1.79e-05	0.000131	CcSEcCtD
Vandetanib—Nausea—Gabapentin—epilepsy syndrome	1.78e-05	0.000131	CcSEcCtD
Vandetanib—Diarrhoea—Topiramate—epilepsy syndrome	1.73e-05	0.000127	CcSEcCtD
Vandetanib—Dizziness—Topiramate—epilepsy syndrome	1.67e-05	0.000123	CcSEcCtD
Vandetanib—Vomiting—Topiramate—epilepsy syndrome	1.61e-05	0.000118	CcSEcCtD
Vandetanib—Rash—Topiramate—epilepsy syndrome	1.59e-05	0.000117	CcSEcCtD
Vandetanib—Dermatitis—Topiramate—epilepsy syndrome	1.59e-05	0.000117	CcSEcCtD
Vandetanib—Headache—Topiramate—epilepsy syndrome	1.58e-05	0.000116	CcSEcCtD
Vandetanib—Nausea—Topiramate—epilepsy syndrome	1.5e-05	0.00011	CcSEcCtD
Vandetanib—FYN—Immune System—JUN—epilepsy syndrome	7.91e-07	6.52e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6ST—epilepsy syndrome	7.9e-07	6.51e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AVP—epilepsy syndrome	7.89e-07	6.5e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—YWHAZ—epilepsy syndrome	7.88e-07	6.49e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—VEGFA—epilepsy syndrome	7.87e-07	6.48e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCR5—epilepsy syndrome	7.87e-07	6.48e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—AKT1—epilepsy syndrome	7.86e-07	6.47e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC2A1—epilepsy syndrome	7.82e-07	6.44e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MMP9—epilepsy syndrome	7.81e-07	6.43e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PRKCB—epilepsy syndrome	7.81e-07	6.43e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—RELA—epilepsy syndrome	7.8e-07	6.43e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MTOR—epilepsy syndrome	7.8e-07	6.43e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—POMC—epilepsy syndrome	7.8e-07	6.43e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NGF—epilepsy syndrome	7.79e-07	6.42e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6ST—epilepsy syndrome	7.78e-07	6.41e-06	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—AKT1—epilepsy syndrome	7.77e-07	6.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGF2—epilepsy syndrome	7.76e-07	6.39e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PLCB1—epilepsy syndrome	7.73e-07	6.37e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MMP9—epilepsy syndrome	7.73e-07	6.36e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TH—epilepsy syndrome	7.7e-07	6.35e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HTR2A—epilepsy syndrome	7.7e-07	6.34e-06	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—AKT1—epilepsy syndrome	7.69e-07	6.34e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—BCL2—epilepsy syndrome	7.69e-07	6.34e-06	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	7.66e-07	6.31e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MTOR—epilepsy syndrome	7.65e-07	6.3e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	7.58e-07	6.25e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCR5—epilepsy syndrome	7.58e-07	6.24e-06	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—AKT1—epilepsy syndrome	7.57e-07	6.24e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—AKT1—epilepsy syndrome	7.55e-07	6.22e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—RELA—epilepsy syndrome	7.52e-07	6.2e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MTOR—epilepsy syndrome	7.5e-07	6.18e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—FGF2—epilepsy syndrome	7.48e-07	6.16e-06	CbGpPWpGaD
Vandetanib—BLK—Immune System—AKT1—epilepsy syndrome	7.47e-07	6.15e-06	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—AKT1—epilepsy syndrome	7.47e-07	6.15e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HES1—epilepsy syndrome	7.46e-07	6.15e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	7.46e-07	6.14e-06	CbGpPWpGaD
Vandetanib—FGR—Immune System—AKT1—epilepsy syndrome	7.45e-07	6.13e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CASP3—epilepsy syndrome	7.43e-07	6.12e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—epilepsy syndrome	7.43e-07	6.12e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HTR2A—epilepsy syndrome	7.42e-07	6.11e-06	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—AKT1—epilepsy syndrome	7.41e-07	6.1e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—SRC—epilepsy syndrome	7.39e-07	6.09e-06	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—AKT1—epilepsy syndrome	7.39e-07	6.09e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—POMC—epilepsy syndrome	7.38e-07	6.08e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MTOR—epilepsy syndrome	7.38e-07	6.08e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—SRC—epilepsy syndrome	7.37e-07	6.07e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TSC2—epilepsy syndrome	7.31e-07	6.02e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGT—epilepsy syndrome	7.3e-07	6.02e-06	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—AKT1—epilepsy syndrome	7.27e-07	5.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FYN—epilepsy syndrome	7.26e-07	5.98e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	7.24e-07	5.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—H2AFX—epilepsy syndrome	7.23e-07	5.96e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—POMC—epilepsy syndrome	7.23e-07	5.95e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCL2—epilepsy syndrome	7.22e-07	5.95e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MEF2C—epilepsy syndrome	7.22e-07	5.95e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—JUN—epilepsy syndrome	7.22e-07	5.94e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—SRC—epilepsy syndrome	7.21e-07	5.94e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—SRC—epilepsy syndrome	7.2e-07	5.93e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—VEGFA—epilepsy syndrome	7.2e-07	5.93e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—SRC—epilepsy syndrome	7.18e-07	5.91e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CASP3—epilepsy syndrome	7.18e-07	5.91e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGF2—epilepsy syndrome	7.17e-07	5.91e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—APOE—epilepsy syndrome	7.16e-07	5.89e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—SRC—epilepsy syndrome	7.12e-07	5.87e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—POMC—epilepsy syndrome	7.12e-07	5.86e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ALB—epilepsy syndrome	7.11e-07	5.86e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—SRC—epilepsy syndrome	7.1e-07	5.85e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCL2—epilepsy syndrome	7.07e-07	5.83e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MTOR—epilepsy syndrome	7.07e-07	5.82e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1B—epilepsy syndrome	7.06e-07	5.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TSC2—epilepsy syndrome	7.05e-07	5.8e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGT—epilepsy syndrome	7.04e-07	5.8e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP9—epilepsy syndrome	7.02e-07	5.78e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—VEGFA—epilepsy syndrome	7.01e-07	5.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KDR—epilepsy syndrome	7.01e-07	5.77e-06	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—AKT1—epilepsy syndrome	7e-07	5.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—epilepsy syndrome	7e-07	5.77e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—YWHAZ—epilepsy syndrome	6.98e-07	5.75e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—JUN—epilepsy syndrome	6.97e-07	5.74e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCL2—epilepsy syndrome	6.96e-07	5.73e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—VEGFA—epilepsy syndrome	6.94e-07	5.71e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NGF—epilepsy syndrome	6.9e-07	5.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APOE—epilepsy syndrome	6.9e-07	5.68e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—POMC—epilepsy syndrome	6.86e-07	5.65e-06	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—AKT1—epilepsy syndrome	6.85e-07	5.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—JUN—epilepsy syndrome	6.84e-07	5.63e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—BCL2—epilepsy syndrome	6.81e-07	5.61e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MTOR—epilepsy syndrome	6.81e-07	5.61e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—SRC—epilepsy syndrome	6.8e-07	5.6e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1B—epilepsy syndrome	6.8e-07	5.6e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP9—epilepsy syndrome	6.78e-07	5.59e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KDR—epilepsy syndrome	6.76e-07	5.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PRKCB—epilepsy syndrome	6.75e-07	5.56e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—epilepsy syndrome	6.75e-07	5.56e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—SRC—epilepsy syndrome	6.74e-07	5.55e-06	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AKT1—epilepsy syndrome	6.74e-07	5.55e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6ST—epilepsy syndrome	6.72e-07	5.54e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCR5—epilepsy syndrome	6.71e-07	5.53e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—RELA—epilepsy syndrome	6.66e-07	5.48e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—FGF2—epilepsy syndrome	6.62e-07	5.46e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—JUN—epilepsy syndrome	6.59e-07	5.43e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR2A—epilepsy syndrome	6.57e-07	5.41e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—epilepsy syndrome	6.56e-07	5.41e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—SRC—epilepsy syndrome	6.55e-07	5.4e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	6.55e-07	5.39e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	6.55e-07	5.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—epilepsy syndrome	6.54e-07	5.39e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MTOR—epilepsy syndrome	6.53e-07	5.38e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGF2—epilepsy syndrome	6.53e-07	5.38e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PRKCB—epilepsy syndrome	6.5e-07	5.36e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6ST—epilepsy syndrome	6.48e-07	5.34e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SRC—epilepsy syndrome	6.47e-07	5.33e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HMOX1—epilepsy syndrome	6.43e-07	5.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGF2—epilepsy syndrome	6.39e-07	5.26e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAT—epilepsy syndrome	6.34e-07	5.23e-06	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—epilepsy syndrome	6.32e-07	5.21e-06	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—epilepsy syndrome	6.32e-07	5.21e-06	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—epilepsy syndrome	6.31e-07	5.19e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGF2—epilepsy syndrome	6.29e-07	5.18e-06	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—epilepsy syndrome	6.28e-07	5.18e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—epilepsy syndrome	6.26e-07	5.15e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SRC—epilepsy syndrome	6.25e-07	5.15e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TSC2—epilepsy syndrome	6.24e-07	5.14e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGT—epilepsy syndrome	6.23e-07	5.13e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—epilepsy syndrome	6.22e-07	5.12e-06	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—epilepsy syndrome	6.2e-07	5.11e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCB1—epilepsy syndrome	6.17e-07	5.08e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—POMC—epilepsy syndrome	6.15e-07	5.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—SRC—epilepsy syndrome	6.13e-07	5.05e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOE—epilepsy syndrome	6.1e-07	5.03e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—epilepsy syndrome	6.09e-07	5.02e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RELA—epilepsy syndrome	6.06e-07	4.99e-06	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—epilepsy syndrome	6.06e-07	4.99e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MTOR—epilepsy syndrome	6.03e-07	4.97e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—epilepsy syndrome	6.02e-07	4.96e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—epilepsy syndrome	6.01e-07	4.95e-06	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—epilepsy syndrome	6.01e-07	4.95e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SRC—epilepsy syndrome	6.01e-07	4.95e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KDR—epilepsy syndrome	5.98e-07	4.93e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—epilepsy syndrome	5.97e-07	4.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MTOR—epilepsy syndrome	5.94e-07	4.89e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RELA—epilepsy syndrome	5.93e-07	4.89e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—POMC—epilepsy syndrome	5.92e-07	4.88e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—SRC—epilepsy syndrome	5.91e-07	4.87e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RELA—epilepsy syndrome	5.84e-07	4.81e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—JUN—epilepsy syndrome	5.83e-07	4.81e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MTOR—epilepsy syndrome	5.82e-07	4.79e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—epilepsy syndrome	5.8e-07	4.77e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PRKCB—epilepsy syndrome	5.76e-07	4.74e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—epilepsy syndrome	5.74e-07	4.73e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6ST—epilepsy syndrome	5.73e-07	4.72e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MTOR—epilepsy syndrome	5.73e-07	4.72e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—SRC—epilepsy syndrome	5.66e-07	4.66e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—epilepsy syndrome	5.58e-07	4.6e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	5.47e-07	4.51e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—epilepsy syndrome	5.47e-07	4.5e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—SRC—epilepsy syndrome	5.46e-07	4.5e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF2—epilepsy syndrome	5.44e-07	4.48e-06	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—epilepsy syndrome	5.36e-07	4.42e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—epilepsy syndrome	5.35e-07	4.41e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	5.34e-07	4.4e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JUN—epilepsy syndrome	5.31e-07	4.37e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—epilepsy syndrome	5.27e-07	4.34e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—POMC—epilepsy syndrome	5.24e-07	4.32e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF2—epilepsy syndrome	5.24e-07	4.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	5.2e-07	4.29e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JUN—epilepsy syndrome	5.2e-07	4.28e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	5.17e-07	4.26e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—epilepsy syndrome	5.16e-07	4.25e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—epilepsy syndrome	5.13e-07	4.23e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JUN—epilepsy syndrome	5.12e-07	4.22e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—epilepsy syndrome	5.06e-07	4.17e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RELA—epilepsy syndrome	5.05e-07	4.16e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—epilepsy syndrome	5.03e-07	4.14e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—epilepsy syndrome	5.02e-07	4.14e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—epilepsy syndrome	4.98e-07	4.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MTOR—epilepsy syndrome	4.95e-07	4.08e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—epilepsy syndrome	4.93e-07	4.06e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RELA—epilepsy syndrome	4.86e-07	4.01e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—epilepsy syndrome	4.77e-07	3.93e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—epilepsy syndrome	4.76e-07	3.92e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	4.67e-07	3.84e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—epilepsy syndrome	4.66e-07	3.84e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—epilepsy syndrome	4.64e-07	3.82e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF2—epilepsy syndrome	4.64e-07	3.82e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—epilepsy syndrome	4.59e-07	3.78e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—epilepsy syndrome	4.59e-07	3.78e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—epilepsy syndrome	4.58e-07	3.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—epilepsy syndrome	4.55e-07	3.75e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—epilepsy syndrome	4.54e-07	3.74e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—epilepsy syndrome	4.48e-07	3.69e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—epilepsy syndrome	4.48e-07	3.69e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—epilepsy syndrome	4.47e-07	3.68e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—epilepsy syndrome	4.46e-07	3.67e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	4.44e-07	3.66e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—epilepsy syndrome	4.43e-07	3.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	4.42e-07	3.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—epilepsy syndrome	4.42e-07	3.64e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—epilepsy syndrome	4.41e-07	3.63e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—epilepsy syndrome	4.39e-07	3.61e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RELA—epilepsy syndrome	4.3e-07	3.55e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—epilepsy syndrome	4.3e-07	3.54e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—epilepsy syndrome	4.26e-07	3.51e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—POMC—epilepsy syndrome	4.23e-07	3.49e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—epilepsy syndrome	4.23e-07	3.48e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—epilepsy syndrome	4.22e-07	3.48e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	4.22e-07	3.48e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—epilepsy syndrome	4.19e-07	3.45e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	4.17e-07	3.44e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—epilepsy syndrome	4.17e-07	3.44e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TH—epilepsy syndrome	4.16e-07	3.43e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—epilepsy syndrome	4.14e-07	3.41e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—epilepsy syndrome	4.07e-07	3.36e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—epilepsy syndrome	4.02e-07	3.31e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—epilepsy syndrome	3.97e-07	3.27e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—epilepsy syndrome	3.89e-07	3.2e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—epilepsy syndrome	3.88e-07	3.2e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—epilepsy syndrome	3.86e-07	3.18e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—epilepsy syndrome	3.82e-07	3.15e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—epilepsy syndrome	3.81e-07	3.14e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—epilepsy syndrome	3.77e-07	3.11e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—epilepsy syndrome	3.73e-07	3.08e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—epilepsy syndrome	3.72e-07	3.07e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—epilepsy syndrome	3.67e-07	3.03e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—epilepsy syndrome	3.67e-07	3.02e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—epilepsy syndrome	3.52e-07	2.9e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	3.47e-07	2.86e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAT—epilepsy syndrome	3.42e-07	2.82e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—epilepsy syndrome	3.39e-07	2.79e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—epilepsy syndrome	3.38e-07	2.78e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	3.33e-07	2.74e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—epilepsy syndrome	3.29e-07	2.71e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—epilepsy syndrome	3.25e-07	2.68e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—epilepsy syndrome	3.13e-07	2.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	3.1e-07	2.55e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—epilepsy syndrome	3e-07	2.47e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—epilepsy syndrome	2.96e-07	2.44e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—epilepsy syndrome	2.9e-07	2.39e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—epilepsy syndrome	2.85e-07	2.35e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—epilepsy syndrome	2.75e-07	2.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—epilepsy syndrome	2.72e-07	2.24e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—epilepsy syndrome	2.66e-07	2.19e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—epilepsy syndrome	2.46e-07	2.03e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—epilepsy syndrome	2.37e-07	1.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—POMC—epilepsy syndrome	2.29e-07	1.88e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—epilepsy syndrome	2.1e-07	1.73e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—epilepsy syndrome	2.08e-07	1.72e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.82e-07	1.5e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—epilepsy syndrome	1.7e-07	1.4e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	9.16e-08	7.55e-07	CbGpPWpGaD
